Targeted Cancer Therapy‐on‐A‐Chip
Advanced Healthcare Materials · 2024-11 · 13 (29)
DOI: 10.1002/adhm.202400833 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, online erschienen am 05.08.2024. Verfasst von Heba Abed und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical and Biological Engineering, American University of Sharjah, Sharjah, UAE. Hauptthemen laut MEDLINE: Lab-On-A-Chip Devices, Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 388 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Al-Jalila Foundation, Al Qasimi Foundation, the Patient's Friends Committee-Sharjah, Biosciences and Bioengineering Research Institute.
Abstract (Originalsprache)
Targeted cancer therapy (TCT) is gaining increased interest because it reduces the risks of adverse side effects by specifically treating tumor cells. TCT testing has traditionally been performed using two‐dimensional (2D) cell culture and animal studies. Organ‐on‐a‐chip (OoC) platforms have been developed to recapitulate cancer in vitro, as cancer‐on‐a‐chip (CoC), and used for chemotherapeutics development and testing. This review explores the use of CoCs to both develop and test TCTs, with a focus on three main aspects, the use of CoCs to identify target biomarkers for TCT development, the use of CoCs to test free, un‐encapsulated TCTs, and the use of CoCs to test encapsulated TCTs. Despite current challenges such as system scaling, and testing externally triggered TCTs, TCToC shows a promising future to serve as a supportive, pre‐clinical platform to expedite TCT development and bench‐to‐bedside translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemical and Biological Engineering, American University of Sharjah, Sharjah, UAE.
- Materials Science and Engineering PhD program, College of Arts and Sciences, American University of Sharjah, Sharjah, UAE.
- Department of Chemical Engineering, Brigham Young University, Provo, UT, 84602, USA.
- Institute for Quantitative Health Science and Engineering (IQ) and Department of Biomedical Engineering (BME), Michigan State University, East Lansing, MI, 48824, USA.
- Department of Bioengineering, University of California, Los Angeles, Los Angeles, CA, 90095-1600, USA.
ORCID-Profile: Nureddin Ashammakhi, Ghaleb A Husseini
Förderung
- Al-Jalila Foundation
- Al Qasimi Foundation, the Patient's Friends Committee-Sharjah
- Biosciences and Bioengineering Research Institute
- GCC Co-Fund Program
- Takamul Program
- Technology Innovation Pioneer
- Material Science and Engineering Ph.D. program at AUS
- Dana Gas Endowed Chair for Chemical Engineering
Zitieren
APA
Abed, H., Radha, R., Anjum, S., Paul, V., AlSawaftah, N., Pitt, W. G., Ashammakhi, N., & Husseini, G. A. (2024). Targeted Cancer Therapy‐on‐A‐Chip. Advanced Healthcare Materials, 13(29). https://doi.org/10.1002/adhm.202400833
Vancouver
Abed H, Radha R, Anjum S, Paul V, AlSawaftah N, Pitt WG, et al. Targeted Cancer Therapy‐on‐A‐Chip. Advanced Healthcare Materials. 2024;13(29). doi:10.1002/adhm.202400833
BibTeX
@article{Abed2024,
author = {Abed, Heba and Radha, Remya and Anjum, Shabana and Paul, Vinod and AlSawaftah, Nour and Pitt, William G and Ashammakhi, Nureddin and Husseini, Ghaleb A},
title = {Targeted Cancer Therapy‐on‐A‐Chip},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {29},
doi = {10.1002/adhm.202400833}
}
EUVIMED